Top

Published in:

Open Access 01-06-2018 | Original Article

Immune cell expression of TGFβ1 in cancer with lymphoid stroma: dendritic cell and regulatory T cell contact

Authors: Haruo Ohtani, Toru Terashima, Eiichi Sato

Published in: Virchows Archiv | Issue 6/2018

Abstract

Although cancer tissue generally shows limited immune responses, some cancers abound with lymphocytes, which generally show favorable prognosis. These cancers, despite their rarity, are important in analyzing immune responses in cancer tissue. Transforming growth factor β1 (TFGβ1) is a multifunctional cytokine, generally having an immunosuppressive function. The present study analyzes the in situ TGFβ1 expression in 23 cases of lymphocyte-rich gastric carcinomas (Ly-rich GCs) using immunohistochemistry and in situ hybridization. Immunohistochemistry revealed that latency-associated peptide (LAP) of TGFβ1 was localized in mainly immune cells in all cases, which was more abundant than in control GCs. Expression of LAP by cancer cells was only focal. In situ hybridization also confirmed abundant TGFβ1 mRNA expression in the lymphoid stroma. Double immunofluorescent microscopy identified LAP⁺ cells as macrophages, dendritic cells, and part of T cells. Close cell-to-cell contact was observed between LAP⁺ dendritic-shaped cells and FoxP3⁺ regulatory T cells (T_reg cells). Mature dendritic cells in Ly-rich GCs expressed LAP more frequently than those in the secondary lymphoid organs. Our data revealed abundant expression of TGFβ1 in immune cells with contact to T_reg cells in lymphoid stroma, which is consistent with the notion that TGFβ1 is one of the immunosuppressive factors in cancer stroma.

Available only for authorised users

Chen W, Ten Dijke P (2016) Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol 16:723–740. https://doi.org/10.1038/nri.2016.112 CrossRefPubMed

Bierie B, Moses H (2006) TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506–520. https://doi.org/10.1038/nrc1926 CrossRefPubMed

Tian M, Schiemann WP (2009) The TGF-beta paradox in human cancer: an update. Future Oncol 5:259–271. https://doi.org/10.2217/14796694.5.2.259 CrossRefPubMedPubMedCentral

Gigante M, Gesualdo L, Ranieri E (2012) TGF-beta: a master switch in tumor immunity. Curr Pharm Des 18:4126–4134CrossRefPubMed

Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P (2010) The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol 10:554–567. https://doi.org/10.1038/nri2808 CrossRefPubMed

Tu E, Chia PZ, Chen W (2014) TGFβ in T cell biology and tumor immunity: angel or devil? Cytokine Growth Factor Rev 25:423–435. https://doi.org/10.1016/j.cytogfr.2014.07.014 CrossRefPubMedPubMedCentral

Speiser DE, Ho PC, Verdeil G (2016) Regulatory circuits of T cell function in cancer. Nat Rev Immunol 16:599–611. https://doi.org/10.1038/nri.2016.80 CrossRefPubMed

Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H (1996) Immunophenotypical characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8⁺ T-lymphocytes. Lab Investig 75:67–76PubMed

Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O (2009) Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3⁺ T cells in lymphocyte-rich gastric carcinoma. J Pathol 217:21–31. https://doi.org/10.1002/path.2448 CrossRefPubMed

10.

Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H (2015) Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int 65:644–651. https://doi.org/10.1111/pin.12355 CrossRefPubMedPubMedCentral

11.

Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, Kroemer G, Tartour E (2013) Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron 6:147–157. https://doi.org/10.1007/s12307-012-0122-y CrossRefPubMed

12.

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S (2016) Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22:679–684. https://doi.org/10.1038/nm.4086 CrossRefPubMed

13.

Ohtani H, Yoshie O (2010) Morphometric analysis of the balance between CXCR3⁺ T cells and FOXP3⁺ regulatory T cells in lymphocyte-rich and conventional gastric cancers. Virchows Arch 456:615–623. https://doi.org/10.1007/s00428-010-0921-9 CrossRefPubMed

14.

Mizoi T, Ohtani H, Miyazono K, Miyazawa M, Matsuno S, Nagura H (1993) Immunoelectron microscopic localization of transforming growth factor β1 and latent transforming growth factor β1 binding protein in human cancer cells and stromal cells. Cancer Res 53:1–8

15.

Kinugasa S, Abe S, Tachibana M et al (1998) Overexpression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology 55:582–587CrossRefPubMed

16.

Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC (2007) TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res 139:182–188. https://doi.org/10.1016/j.jss.2006.10.005 CrossRefPubMed

17.

Sobin LH, Gospodarowicz MK, Wittekind CH (eds) (2009) UICC TNM classification of malignant tumours, 7th edn. Blackwell Publishing Ltd, West Sussex

18.

Miyazono K, Olofsson A, Colosetti P, Heldin CH (1991) A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 10:1091–1101PubMedPubMedCentralCrossRef

19.

Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886. https://doi.org/10.1084/jem.20030152 CrossRefPubMedPubMedCentral

20.

Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18:1280–1291. https://doi.org/10.1093/emboj/18.5.1280 CrossRefPubMedPubMedCentral

21.

Kobayashi A, Weinberg V, Darragh T, Smith-McCune K (2008) Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 1:412–420. https://doi.org/10.1038/mi.2008.33 CrossRefPubMed

22.

Bonertz A, Weitz J, Pietsch DH et al (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119:3311–3321. https://doi.org/10.1172/JCI39608. PubMedPubMedCentralCrossRef

23.

Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD (2009) Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 182:2795–2807. https://doi.org/10.4049/jimmunol.0712671 CrossRefPubMed

24.

Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, Segura E, Tussiwand R, Yona S (2014) Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol 14:571–578. https://doi.org/10.1038/nri3712 CrossRefPubMedPubMedCentral

25.

Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH (2014) Tertiary lymphoid structures in cancer and beyond. Trends Immunol 35:571–580. https://doi.org/10.1016/j.it.2014.09.006 CrossRefPubMed

26.

Terabe M, Robertson FC, Clark K, de Ravin E, Bloom A, Venzon DJ, Kato S, Mirza A, Berzofsky JA (2017) Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncoimmunology 6(5):e1308616. https://doi.org/10.1080/2162402X.2017.1308616 CrossRefPubMedPubMedCentral

27.

Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, V. Artemov A, Wysocki PT, Mehra R, Nimmagadda S, Marchionni L, Sidransky D, Borrello IM, Izumchenko E, Bedi A (2018) Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nat Commun 9:741. https://doi.org/10.1038/s41467-017-02696-6 CrossRefPubMedPubMedCentral

Title: Immune cell expression of TGFβ1 in cancer with lymphoid stroma: dendritic cell and regulatory T cell contact
Authors: Haruo Ohtani
Toru Terashima
Eiichi Sato
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 6/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2336-y

ACC 2024 Congress

Springer Medicine

Immune cell expression of TGFβ1 in cancer with lymphoid stroma: dendritic cell and regulatory T cell contact

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Pathologist’s assistant (PathA) and his/her role in the surgical pathology department: a systematic review and a narrative synthesis

Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer

Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder

Extra-axial chordoma: a clinicopathologic analysis of six cases

Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients

The more the micropapillary pattern in stage I lung adenocarcinoma, the worse the prognosis—a retrospective study on digitalized slides